CSIMarket Company Name, Ticker, Competitors, else..
 
Inhibrx Biosciences Inc   (NASDAQ: INBX)
Other Ticker:  
 
 
Price: $13.4900 $-0.05 -0.369%
Day's High: $13.8965 Week Perf: -1.1 %
Day's Low: $ 13.24 30 Day Perf: -7.35 %
Volume (M): 44 52 Wk High: $ 39.79
Volume (M$): $ 596 52 Wk Avg: $22.32
Open: $13.55 52 Wk Low: $10.80



 Market Capitalization (Millions $) 209
 Shares Outstanding (Millions) 15
 Employees 89
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 1,642
 Cash Flow (TTM) (Millions $) -141
 Capital Exp. (TTM) (Millions $) 6

Inhibrx Biosciences Inc
Inhibrx Inc is a biopharmaceutical company that specializes in the development of innovative antibody therapeutics. The company focuses on creating therapeutics for the treatment of various diseases, including cancer, immunological disorders, and rare genetic diseases.

Inhibrx utilizes a proprietary platform called single-domain antibody (sdAb) technology, which allows for the creation of highly specific and potent antibodies. These sdAbs have the ability to target and bind to specific disease-causing proteins, known as antigens, with high affinity.

The company's sdAb-based therapeutics have the potential to provide significant benefits over traditional antibody therapies, including improved tissue penetration, increased stability, and enhanced safety profiles. Inhibrx is dedicated to advancing these innovative treatments through rigorous preclinical and clinical development.

Inhibrx collaborates with pharmaceutical companies, research institutions, and healthcare organizations to accelerate the development and commercialization of its novel antibody therapeutics. The company is committed to making a meaningful impact on patients' lives by providing new treatment options for a range of debilitating and life-threatening diseases.


   Company Address: 11025 N. Torrey Pines Road La Jolla 92037 CA
   Company Phone Number: 795-4220   Stock Exchange / Ticker: NASDAQ INBX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADAP   -2.59%    
AMGN        0.71% 
BIIB   -6.41%    
CCCC        12.57% 
EXEL        2.55% 
RLAY   -6.69%    
• View Complete Report
   



Inhibrx Biosciences Inc

Inhibrx Inc. Soars: A Remarkable Financial Turnaround Sets Stage for Future Success!


(approximately 50 words):
In recent times, Inhibrx Inc., a prominent biotech company specializing in biological products, has witnessed a series of noteworthy events that have contributed to fluctuations in its stock performance. This article aims to delve into these events and how they might shape the future trajectory of Inhibrx Inc.
1. Surging Revenue Growth and Turnaround (approximately 70 words):
In its most recent fiscal period ending June 30, 2024, Inhibrx Inc. experienced an astounding 233.333% year-on-year revenue advance, reaching $0.10 million. This growth was accompanied by a positive turnaround in earnings per share (EPS), with the company exhibiting an impressive $125.48 EPS, a significant improvement from the prior quarter's negative $-1.44 EPS. This newfound profitability highlights the potential strength of Inhibrx Inc.'s business operations.
Stocks on the Move

Inhibrx Inc. Shares Experience Volatility Amidst Recent Events

Published Wed, Jun 26 2024 4:41 PM UTC

(Approximately 100 words):Inhibrx Inc., a biotech company specializing in biological products, has been at the center of several significant events and developments in recent weeks. These events have led to increased volatility in the company s stock performance. In this article, we will examine the reasons behind Inhibrx Inc. s fluctuating shares and shed light on the vari...
Inhibrx Inc

Inhibrx Inc maintains steady revenue stream in Q1 2024, mirroring previous year's performance

In the latest financial report released by Inhibrx Inc for the January to March 31, 2024 period, the company has reported widening losses of $-1.44 per share compared to $-1.12 per share in the same period the year prior. However, there was a slight improvement in earnings per share (EPS) from $-1.50 per share in the previous reporting period. Despite the losses, the revenue for this period remained flat at $0.00 million, the same as the previous year and a decrease from $1.63 million sequentially.
The net loss for Inhibrx Inc for the January to March 31, 2024 period was reported at $-78.710 million, which is a significant increase from the $-48.916 million loss reported in the same period the year before.
Inhibrx Inc

Inhibrx Inc Faces Profitability Challenges Despite Revenue Surge in Q4 2023

Inhibrx Inc, a biotechnology and pharmaceuticals company, has announced impressive financial results for the fourth quarter of 2023. Despite the challenging market conditions faced by many companies in the sector, Inhibrx Inc saw a significant improvement in revenue, with a 496.35% year-on-year increase to $1.63 million. However, the company also reported an increased shortfall per share at $-1.50.
Compared to the previous reporting period, the shortfall per share advanced from $-1.10, while revenue more than doubled by 1273.109% from $0.12 million. Inhibrx Inc's net shortfall for the fourth quarter of 2023 was $-93.604 million, which is larger than the $-40.915 million reported in the same period a year ago.
Inhibrx Inc

Diminishing Returns Expand at Biotechnology & Pharmaceuticals Company Throughout July-September 2023 Fiscal Period, Inhibrx Inc. Takes More Sophisticated Approach

Inhibrx Inc, a biopharmaceutical company, has recently disclosed its third quarter financial report for 2023, which showed a significant decline in revenue. The company's revenue decreased by -57.194% to $0.12 million compared to the same quarter last year. Additionally, the shortfall per share increased to $-1.10 from the previous year's corresponding quarter.
In comparison to the previous quarter, where the company reported a shortfall per share of $-1.08, there has been a slight improvement with revenue doubling by 296.667% to $0.03 million.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com